CETUXIMAB IN COMBINATION WITH XELIRI OR XELOX IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Ocvirk, Janja [1 ]
Rebersek, Martina [1 ]
Boc, Marko [1 ]
Mesti, Tanja [1 ]
Moltara, Maja Ebert [1 ]
机构：
[1] Inst Oncol Ljubljana, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v96 / v96
页数：1
相关论文
共 50 条
  • [31] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
    Bokemeyer, Carsten
    Bondarenko, Igor
    Makhson, Anatoly
    Hartmann, Joerg T.
    Aparicio, Jorge
    de Braud, Filippo
    Donea, Serban
    Ludwig, Heinz
    Schuch, Gunter
    Stroh, Christopher
    Loos, Anja H.
    Zubel, Angela
    Koralewski, Piotr
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 663 - 671
  • [32] Pharmacoeconomic analysis of XELOX versus FOLFOX for metastatic colorectal cancer first-line treatment in Taiwan
    Chen, H. -H.
    Chang, C. -S.
    Chen, L. -T.
    Chen, W. T. -L.
    Hsu, T. -C.
    Wang, J. -Y.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 54 - 54
  • [33] Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer
    Grande, Carlos
    Quintero, Guillermo
    Candamio, Sonia
    Paris Bouzas, Lorena
    Jose Villanueva, Maria
    Campos, Begona
    Gallardo, Elena
    Alvarez, Elena
    Casal, Joaquin
    Ramon Mel, Jose
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (02) : 114 - 121
  • [34] Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    [J]. ANTICANCER RESEARCH, 2011, 31 (05) : 1777 - 1782
  • [35] Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
    Heinemann, V.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H. G.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [38] XELOX AND BEVACIZUMAB AS FIRST-LINE TREATMENT IN FIT ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER: THE BOXE STUDY
    Rosati, Gerardo
    Avallone, Antonio
    Aprile, Giuseppe
    Butera, Alfredo
    De Pauli, Federica
    Reggiardo, Giorgio
    Bilancia, Domenico
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [39] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [40] How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Lindsay, Colin R.
    Roxburgh, Patricia
    Graham, Janet
    [J]. FUTURE ONCOLOGY, 2013, 9 (06) : 825 - 829
12345